Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
104
resultados
Última actualización
21/06/2025 [08:47:00]
Resultados 75 a 100 de 104
Resumen de: US2025171753A1
The present invention relates to a peptide comprising an amino acid sequence EX1EAX2SGSS according to SEQ ID No. 1, or a pharmaceutically acceptable salt thereof, wherein X1 and X2 independently represent a linker which links the adjoining amino acids or an amino acid deletion, and wherein the peptide has an overall length in the range of from 7 to 30 amino acids. The present invention further relates to a pharmaceutical composition comprising the peptide, and the peptide for use in the preventive treatment of acute lymphoblastic leukemia, myelodysplastic syndrome or acute myeloid leukemia, particularly therapy-related acute lymphoblastic leukemia, therapy-related myelodysplastic syndrome or therapy-related acute myeloid leukemia.
Resumen de: AU2025203224A1
The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
Resumen de: US2025161279A1
The present disclosure provides methods of treating multiple myeloma in a subject with a Bcl-2 inhibitor, in particularly 2-((1H-pyrrolo 2,3-bpyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro3.5nonan-7-yl)benzamide or a pharmaceutically acceptable salt thereof, or in combination with dexamethasone.
Resumen de: CN119497710A
Compounds, compositions, and methods for treating cancers characterized by aberrant B cell lymphoma 6 (BCL6) activity are described.
Resumen de: EP4559902A2
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
Resumen de: EP4559477A2
The present application provides compositions and methods for treating cancers, including follicular lymphoma, T cell lymphoma and adenoid cystic carcinoma, using an anti-CD137 antibody that specifically binds to an extracellular domain of human CD137. In some embodiment, combination therapies including the anti-CD137 antibody and an immune checkpoint inhibitor, and/or a chemotherapeutic agent are provided. Biomarkers such as total CD137, membrane bound CD137 (mCD137), soluble CD137 (sCD137), CD137 ligand, Ki67, CD8+ effector memory T (T<sub>em</sub>) cells, regulatory T (T<sub>reg</sub>) cells, and natural killer (NK) cell levels for the methods of treatment described herein are also provided.
Resumen de: US2025170160A1
Methods of monitoring therapeutic efficacy in a subject with MDS are provided. Also provided is a method of identifying a subject with myelodysplastic syndrome (MDS) for treatment with a telomerase inhibitor, and methods of treating MDS. The subject methods can include administering to the subject an effective amount of a telomerase inhibitor and assessing the hTERT expression levels in a biological sample obtained from the subject. In some cases, a 50% or greater reduction in hTERT expression level identifies a subject who has an increased likelihood of benefiting from treatment with the telomerase inhibitor. The subject can be naive to treatment with a HMA, lenalidomide, or both. In some cases, the subject is classified as having low or intermediate-1 IPSS risk MDS and/or MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA). In some instances, the telomerase inhibitor is imetelstat sodium.
Resumen de: AU2023355219A1
The present invention relates to immune cells co-expressing IL-15 and a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain, and to a composition for preventing or treating cancer comprising same as an active ingredient. The immune cells according to the present invention not only exhibit synergistic tumor cell killing activity through co-expression of the chimeric antigen receptor and IL-15, but also significantly improve survival and in vitro proliferation rates, and can thus be usefully employed as an efficient anti-cancer cell therapy. In particular, when the immune cells of the present invention express a chimeric antigen receptor targeting CD5, the immune cells can be used as an effective treatment composition for various CD5-positive tumors, including lymphocytic leukemia.
Resumen de: AU2023379583A1
Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express cytotoxic chimeric receptors and various dosing regimens for administering such cells. In several embodiments, the immune cells express a chimeric receptor that targets ligands of NKG2D on tumor cells. In several embodiments, the cancer is a blood cancer, for example, acute myeloid leukemia (e.g., relapsed/refractory acute myeloid leukemia) or myelodysplastic syndrome. In several embodiments, the tumor is a solid tumor, for example, breast cancer, cervical cancer, colorectal cancer, gastric cancer, head and neck cancers, hepatocellular carcinoma, lung cancer, melanoma, intrahepatic cholangiocarcinoma or other liver tumor, for example, secondary metastases from colorectal cancer. In several embodiments, the immune cells are administered in conjunction with a therapeutic agent, such as an additional anti-cancer agent.
Resumen de: AU2023376971A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Resumen de: US2025161279A1
The present disclosure provides methods of treating multiple myeloma in a subject with a Bcl-2 inhibitor, in particularly 2-((1H-pyrrolo 2,3-bpyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro3.5nonan-7-yl)benzamide or a pharmaceutically acceptable salt thereof, or in combination with dexamethasone.
Resumen de: US2025161248A1
A method for treating chronic myelomonocytic leukemia (CMML), or for maintaining or enhancing the proliferation of wildtype hematopoietic stem cells in patients suffering from CMML, by administering to a patient in need thereof a pharmaceutical composition containing an effective amount of an inhibitor of the CXCL8 receptor.
Resumen de: US2025163096A1
The present invention relates to chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositions comprising the compounds. The compounds may, in particular, be useful in the treatment of leukaemia, lymphoma and/or solid tumours in Homo sapiens. The compounds are derivatives of cordycepin (3′-deoxyadenosine).
Resumen de: US2025163066A1
The present invention is directed to the compounds of Formula (I)—PROTACs of MALT1. The PROTACs described herein can be useful in the treatment of diseases or disorders associated with MALT1, such as lymphoma. In particular, the invention is concerned with compounds and pharmaceutical compositions degrade MALT1, methods of treating diseases or disorders associated with MALT1, and methods of synthesizing these compounds.
Resumen de: US2025163174A1
The invention provides antibodies which bind to LY75. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including pancreatic cancer, ovarian cancer, breast cancer, colorectal cancer, esophageal cancer, skin cancer, thyroid cancer, lung cancer, multiple myeloma and lymphoma.
Resumen de: US2025163146A1
Graft-versus-host disease (GVHD) prophylaxis often consists of calcineurin inhibitor-based combinations that indiscriminately curtail T cell receptor signal transduction. This broad inactivation consequently impairs the function of alloreactive pathogenic T cells as well as beneficial regulatory T cells (Treg) and anti-tumor cytotoxic T lymphocytes (CTL). Due to this non-selective approach, GVHD prevention is incomplete and the graft-versus-leukemia (GVL) effect is jeopardized. Disclosed are isolated binding molecules that disrupt the interaction of DLL4 and Notchl and methods of their use, including, but not limited to the treatment of graft versus host disease.
Resumen de: US2025163172A1
Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
Resumen de: US2025161412A1
Compositions and methods are provided to treat and prevent cancers, such as myelomas, and include adoptive cell therapies in combination with an IL-15 superagonist and one or more chemotherapeutic agents.
Resumen de: US2025163388A1
Disclosed herein are methods of deriving, producing, maintaining, or expanding embryonic stem cells (ESCs) from avian species and a culture medium used for such methods. According to various embodiments, the method includes culturing an embryo extracted from an avian egg in a culture medium to harvest cells from yolk of the avian egg; dissociating cells from the cultured embryo; isolating a morphologically undifferentiated ESC colony from the dissociated cells in a culture medium; and culturing the isolated ESC colony in the presence of ovotransferrin, thereby deriving ESCs. According to various embodiments, the culture medium includes a Wnt inhibitor; a protein kinase C (PKC) inhibitor; ovotransferrin; an inhibitor of activin receptor-like kinases-4, -5, and -7; and a leukemia inhibitory factor (LIF).
Resumen de: WO2025104669A1
The disclosure provides methods of treating a refractory or relapsed acute myeloid leukemia (AML) in a subject comprising administration of a cell comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antigen-binding fragment thereof that binds IL-1RAP, a transmembrane domain, and an intracellular signaling domain comprising at least a stimulatory domain, wherein prior to administering the cell, the subject is preconditioned with a lymphodepleting chemotherapy (LDC).
Resumen de: WO2025106474A1
The invention provides therapeutic and diagnostic methods for the treatment of cancer, such as multiple myeloma (MM), with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: WO2025104184A1
The present invention provides an in vitro method of generating a haematopoietic cell, the method comprising: a) Providing a cell genetically modified to comprise a nucleotide sequence(s) encoding exogenous transcription factors, the exogenous transcription factors comprising an ETS family transcription factor, T-cell acute lymphocytic leukaemia protein 1 (Tal1) and a GATA family transcription factor, wherein expression of the exogenous transcription factors from the nucleotide sequence(s) is inducible by culture with an inducer, and wherein the cell comprises a detectable expression level of the exogenous transcription factors; and b) Culturing the genetically modified cell in a differentiation medium which does not comprise the inducer, such that the expression level of the exogenous transcription factors in the cell is reduced to a level whereby the cell differentiates into a haematopoietic cell. Also provided are genetically modified haematopoietic cells, genetically modified cells and therapeutic uses thereof.
Resumen de: WO2025104045A1
The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.
Resumen de: AU2023385479A1
Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by 3-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.
Nº publicación: AU2023361041A1 22/05/2025
Solicitante:
CHIESI FARM S P A
CHIESI FARMACEUTICI S.P.A
Resumen de: AU2023361041A1
The invention is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular the invention is directed to a modified-release formulation in form of mini-tablets suitable for twice-a-day oral administration for the treatment of diseases which cause an overload of iron for example, thalassemia, sickle cell anemia, hemochromatosis, and myelodysplasia, or for the prevention and/or treatment of diseases which are caused by an overload of iron. The invention is also directed to methods of making said formulation.
BOPI
Sede Electrónica
